APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer
Public ClinicalTrials.gov record NCT00652340. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
APRiCOT-L (Apricoxib in Combination Oncology Treatment - Lung) A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Erlotinib in Non-Small Cell Lung Cancer Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will compare the anti-tumor efficacy of apricoxib and erlotinib with placebo and erlotinib as measured by time to disease progression to test the hypothesis that down regulation of COX-2 and EGFR pathways in patients with up-regulated COX-2 expression in tumor will have a clinical benefit compared with erlotinib alone.
Study identification
- NCT ID
- NCT00652340
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 120 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2008 (Type not available)
- Primary completion
- Jun 2010 (Actual)
- Completion
- Mar 2012 (Actual)
- Last update posted
- Apr 9, 2012
2008 – 2012
United States locations
- U.S. sites
- 47
- U.S. states
- 24
- U.S. cities
- 47
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Tucson | Arizona | — | — |
| Not listed | Bakersfield | California | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Rancho Mirage | California | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | San Dimas | California | — | — |
| Not listed | Stockton | California | — | — |
| Not listed | Norwich | Connecticut | — | — |
| Not listed | Lake North | Florida | — | — |
| Not listed | Lakeland | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Savannah | Georgia | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Kokomo | Indiana | — | — |
| Not listed | New Albany | Indiana | — | — |
| Not listed | Waterloo | Iowa | — | — |
| Not listed | Louisville | Kentucky | — | — |
| Not listed | New Orleans | Louisiana | — | — |
| Not listed | Ann Arbor | Michigan | — | — |
| Not listed | Jackson | Michigan | — | — |
| Not listed | Lansing | Michigan | — | — |
| Not listed | Livonia | Michigan | — | — |
| Not listed | Saginaw | Michigan | — | — |
| Not listed | Saint Joseph | Michigan | — | — |
| Not listed | Robbinsdale | Minnesota | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Neptune City | New Jersey | — | — |
| Not listed | Elmhurst | New York | — | — |
| Not listed | Stony Brook | New York | — | — |
| Not listed | Gastonia | North Carolina | — | — |
| Not listed | Wilmington | North Carolina | — | — |
| Not listed | Akron | Ohio | — | — |
| Not listed | Canton | Ohio | — | — |
| Not listed | Columbus | Ohio | — | — |
| Not listed | Jefferson | Ohio | — | — |
| Not listed | Sylvania | Ohio | — | — |
| Not listed | Corvallis | Oregon | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Upland | Pennsylvania | — | — |
| Not listed | Charleston | South Carolina | — | — |
| Not listed | Arlington | Texas | — | — |
| Not listed | Galveston | Texas | — | — |
| Not listed | Newport News | Virginia | — | — |
| Not listed | Richmond | Virginia | — | — |
| Not listed | Tacoma | Washington | — | — |
| Not listed | Huntington | West Virginia | — | — |
| Not listed | Morgantown | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00652340, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 9, 2012 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00652340 live on ClinicalTrials.gov.